• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌中miR-222-3p上皮-间质转化相关靶基因的鉴定与综合分析

Identification and comprehensive analysis of epithelial-mesenchymal transition related target genes of miR-222-3p in breast cancer.

作者信息

Fang Yutong, Zhang Qunchen, Chen Chunfa, Chen Zexiao, Zheng Rongji, She Chuanghong, Zhang Rendong, Wu Jundong

机构信息

The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.

The Department of Central Laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.

出版信息

Front Oncol. 2023 Jul 20;13:1189635. doi: 10.3389/fonc.2023.1189635. eCollection 2023.

DOI:10.3389/fonc.2023.1189635
PMID:37546414
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10400091/
Abstract

BACKGROUND

Epithelial-mesenchymal transition (EMT) is a crucial mechanism that microRNA-222-3p (miR-222-3p) promotes breast cancer (BC) progression. Our study aimed to identify EMT-associated target genes (ETGs) of miR-222-3p for further analysis of their roles in BC based on bioinformatics tools.

METHODS

Based on bioinformatics analysis, we identified 10 core ETGs of miR-222-3p. Then, we performed a comprehensive analysis of 10 ETGs and miR-222-3p, including pathway enrichment analysis of ETGs, differential expression, clinical significance, correlation with immune cell infiltration, immune checkpoint genes (ICGs) expression, tumor mutational burden (TMB), microsatellite instability (MSI), stemness, drug sensitivity, and genetic alteration.

RESULTS

The expression of miR222-3p in basal-like BC was significantly higher than in other subtypes of BC and the normal adjacent tissue. Pathway analysis suggested that the ETGs might regulate the EMT process via the PI3K-Akt and HIF-1 signaling pathway. Six of the 10 core ETGs of miR-222-3p identified were down-expressed in BC, which were , and , and , and were up-expressed in BC, which also showed potential diagnostic values in BC. Prognosis analysis revealed that higher and expressions were related to a better prognosis, and higher BIRC5 and miR-222-3p expressions were related to a worse prognosis. Most ETGs and miR-222-3p were positively correlated with various infiltration of various immune cells and ICGs expression. Lower TMB scores were correlated with higher expression of and , and higher was related to a higher TMB score. Lower expression of , , and were associated with higher MSI scores. Higher expression of ETGs was associated with lower mRNAsi scores, except and miR-222-3p conversely. Most ETGs and miR-222-3p expression were negatively correlated with the drug IC50 values. The analysis of the genetic alteration of the ETGs suggested that amplification was the main genetic alteration of eight ETGs except for and .

CONCLUSION

MiR-222-3p might be a specific biomarker of basal-like BC. We successfully identify 10 core ETGs of miR-222-3p, some might be useful diagnostic and prognostic biomarkers. The comprehensive analysis of 10 ETGs and miR-222-3p indicated that they might be involved in the development of BC, which might be novel therapeutic targets for the treatment of BC.

摘要

背景

上皮-间质转化(EMT)是一种关键机制,微小RNA-222-3p(miR-222-3p)可促进乳腺癌(BC)进展。我们的研究旨在基于生物信息学工具鉴定miR-222-3p的EMT相关靶基因(ETGs),以进一步分析它们在BC中的作用。

方法

基于生物信息学分析,我们鉴定了miR-222-3p的10个核心ETGs。然后,我们对10个ETGs和miR-222-3p进行了全面分析,包括ETGs的通路富集分析、差异表达、临床意义、与免疫细胞浸润的相关性、免疫检查点基因(ICGs)表达、肿瘤突变负荷(TMB)、微卫星不稳定性(MSI)、干性、药物敏感性和基因改变。

结果

miR222-3p在基底样BC中的表达显著高于其他BC亚型和正常相邻组织。通路分析表明,ETGs可能通过PI3K-Akt和HIF-1信号通路调节EMT过程。鉴定出的miR-222-3p的10个核心ETGs中有6个在BC中低表达,分别是 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/13f0e94b65b6/fonc-13-1189635-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/f858609de73b/fonc-13-1189635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/f46812286b7e/fonc-13-1189635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/ec31536113ef/fonc-13-1189635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/a1003494d455/fonc-13-1189635-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/e55eee60c170/fonc-13-1189635-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/df092f56123f/fonc-13-1189635-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/3267d4fb2c15/fonc-13-1189635-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/097face661ee/fonc-13-1189635-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/f30e84b8f6e9/fonc-13-1189635-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/7ce4ed06d7a7/fonc-13-1189635-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/32e205bca007/fonc-13-1189635-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/38ff5c88f5c5/fonc-13-1189635-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/980b9ef933c0/fonc-13-1189635-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/13f0e94b65b6/fonc-13-1189635-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/f858609de73b/fonc-13-1189635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/f46812286b7e/fonc-13-1189635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/ec31536113ef/fonc-13-1189635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/a1003494d455/fonc-13-1189635-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/e55eee60c170/fonc-13-1189635-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/df092f56123f/fonc-13-1189635-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/3267d4fb2c15/fonc-13-1189635-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/097face661ee/fonc-13-1189635-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/f30e84b8f6e9/fonc-13-1189635-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/7ce4ed06d7a7/fonc-13-1189635-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/32e205bca007/fonc-13-1189635-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/38ff5c88f5c5/fonc-13-1189635-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/980b9ef933c0/fonc-13-1189635-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ca/10400091/13f0e94b65b6/fonc-13-1189635-g014.jpg

相似文献

1
Identification and comprehensive analysis of epithelial-mesenchymal transition related target genes of miR-222-3p in breast cancer.乳腺癌中miR-222-3p上皮-间质转化相关靶基因的鉴定与综合分析
Front Oncol. 2023 Jul 20;13:1189635. doi: 10.3389/fonc.2023.1189635. eCollection 2023.
2
Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer.乳腺癌中 miR-221-3p 及其关键靶基因与上皮-间充质转化相关的临床意义及免疫特征分析。
Aging (Albany NY). 2024 Jan 6;16(1):322-347. doi: 10.18632/aging.205370.
3
Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1.外泌体微小RNA-221-3p通过靶向PIK3R1赋予乳腺癌细胞阿霉素抗性。
Front Oncol. 2020 Apr 30;10:441. doi: 10.3389/fonc.2020.00441. eCollection 2020.
4
Identification of Serum miR-501-3p and miR-338-3p as Novel Diagnostic Biomarkers for Breast Cancer and Their Target Genes Associated with Immune Infiltration.血清miR-501-3p和miR-338-3p作为乳腺癌新型诊断生物标志物及其与免疫浸润相关的靶基因的鉴定。
Int J Gen Med. 2023 Apr 13;16:1279-1294. doi: 10.2147/IJGM.S406802. eCollection 2023.
5
Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.长链非编码 RNA H19 作为 miR-340-3p 的海绵体,通过调节紫杉醇耐药乳腺癌细胞中 YWHAZ 的表达促进上皮-间充质转化。
Environ Toxicol. 2020 Sep;35(9):1015-1028. doi: 10.1002/tox.22938. Epub 2020 May 18.
6
MicroRNA-328-3p inhibits the tumorigenesis of bladder cancer through targeting ITGA5 and inactivating PI3K/AKT pathway.微小RNA-328-3p通过靶向整合素α5(ITGA5)并使PI3K/AKT信号通路失活来抑制膀胱癌的肿瘤发生。
Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5139-5148. doi: 10.26355/eurrev_201906_18178.
7
Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.铜死亡相关 ceRNA 网络的综合分析提示 ER 阳性乳腺癌潜在的内分泌治疗抵抗机制。
BMC Med Genomics. 2023 May 5;16(1):96. doi: 10.1186/s12920-023-01511-0.
8
Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.miR-101-3p在乳腺癌中的临床价值及其潜在靶点的生物学分析:基于癌症基因组图谱(TCGA)和生物信息学的研究
Med Sci Monit. 2017 Apr 18;23:1857-1871. doi: 10.12659/msm.900030.
9
MicroRNA-372-3p promotes the epithelial-mesenchymal transition in breast carcinoma by activating the Wnt pathway.微小RNA-372-3p通过激活Wnt信号通路促进乳腺癌的上皮-间质转化。
J BUON. 2018 Sep-Oct;23(5):1309-1315.
10
LINC01433/miR-2116-3p/MYC Feedback Loop Promotes Cell Proliferation, Migration, and the Epithelial-Mesenchymal Transition in Breast Cancer.LINC01433/miR-2116-3p/MYC 反馈环路促进乳腺癌细胞增殖、迁移和上皮-间充质转化。
Cancer Biother Radiopharm. 2019 Aug;34(6):388-397. doi: 10.1089/cbr.2019.2772. Epub 2019 Apr 2.

引用本文的文献

1
Expression of SOX10, and micro-RNA 221 and Micro-RNA 222 in Oral Squamous Cell Carcinoma and Correlation with Clinicopathological Characteristics.SOX10、微小RNA 221和微小RNA 222在口腔鳞状细胞癌中的表达及其与临床病理特征的相关性
Head Neck Pathol. 2025 Jun 25;19(1):76. doi: 10.1007/s12105-025-01809-8.
2
The SLC26A4-AS1/NTRK2 axis in breast cancer: insights into the ceRNA network and implications for prognosis and immune microenvironment.乳腺癌中的SLC26A4-AS1/NTRK2轴:对ceRNA网络的见解及其对预后和免疫微环境的影响
Discov Oncol. 2025 Mar 16;16(1):329. doi: 10.1007/s12672-025-02080-7.
3
From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.

本文引用的文献

1
LncRNA T376626 is a promising serum biomarker and promotes proliferation, migration, and invasion via binding to LAMC2 in triple-negative breast cancer.长链非编码 RNA T376626 是一种有前途的血清生物标志物,通过与三阴性乳腺癌中的 LAMC2 结合,促进增殖、迁移和侵袭。
Gene. 2023 Apr 15;860:147227. doi: 10.1016/j.gene.2023.147227. Epub 2023 Jan 26.
2
Advances in MUC1-Mediated Breast Cancer Immunotherapy.MUC1 介导的乳腺癌免疫治疗进展。
Biomolecules. 2022 Jul 6;12(7):952. doi: 10.3390/biom12070952.
3
Exploring the Potential of Exosome-Related LncRNA Pairs as Predictors for Immune Microenvironment, Survival Outcome, and Microbiotain Landscape in Esophageal Squamous Cell Carcinoma.
从NTRK基因的基因组谱到其抑制剂的不良反应,一项基于基因组的全面真实世界药物警戒分析。
Front Pharmacol. 2024 Jan 31;15:1329409. doi: 10.3389/fphar.2024.1329409. eCollection 2024.
探讨外泌体相关长链非编码 RNA 对作为预测食管鳞癌免疫微环境、生存结局和微生物组景观的标志物的潜力。
Front Immunol. 2022 Jul 8;13:918154. doi: 10.3389/fimmu.2022.918154. eCollection 2022.
4
The Role of MicroRNA in the Regulation of Tumor Epithelial-Mesenchymal Transition.miRNA 在肿瘤上皮间质转化调控中的作用。
Cells. 2022 Jun 21;11(13):1981. doi: 10.3390/cells11131981.
5
Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors.在人类肿瘤中分析 PIK3R1 和 PIK3R2 作用的泛癌症分析。
Sci Rep. 2022 Apr 8;12(1):5924. doi: 10.1038/s41598-022-09889-0.
6
IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment.白细胞介素 6 细胞因子家族:乳腺癌预防和治疗的潜在靶点。
Int J Mol Sci. 2022 Feb 5;23(3):1809. doi: 10.3390/ijms23031809.
7
MiRNAs and Cancer: Key Link in Diagnosis and Therapy.miRNAs 与癌症:诊断与治疗的关键联系
Genes (Basel). 2021 Aug 23;12(8):1289. doi: 10.3390/genes12081289.
8
Graphene-based nanomaterials for breast cancer treatment: promising therapeutic strategies.基于石墨烯的纳米材料在乳腺癌治疗中的应用:有前途的治疗策略。
J Nanobiotechnology. 2021 Jul 15;19(1):211. doi: 10.1186/s12951-021-00902-8.
9
Neuropilin-1 predicts poor prognosis and promotes tumor metastasis through epithelial-mesenchymal transition in gastric cancer.神经纤毛蛋白-1预示胃癌预后不良,并通过上皮-间质转化促进肿瘤转移。
J Cancer. 2021 Apr 30;12(12):3648-3659. doi: 10.7150/jca.52851. eCollection 2021.
10
Intrahepatic Cholangiocarcinoma Cells Promote Epithelial-mesenchymal Transition of Hepatocellular Carcinoma Cells by Secreting LAMC2.肝内胆管癌细胞通过分泌LAMC2促进肝癌细胞的上皮-间质转化。
J Cancer. 2021 Apr 19;12(12):3448-3457. doi: 10.7150/jca.55627. eCollection 2021.